SCOTUS decision on 'skinny' label generic drugs sparks concerns for future carve outs.

The US Supreme Court has declined to take up a case involving "skinny" label generic drugs, which could have implications for the generic drug industry. The industry has been able to bring generic drugs to market by carving out the label to avoid certain indications that are still under patent protection. The case in question involved a court battle between Teva and GlaxoSmithKline over GSK’s beta-blocker Coreg (carvedilol), which Teva launched a generic of in 2007.